Zejula
Zejula Monotherapy Approved for Some Late-Line Gyn Cancers
The FDA granted approval for an expanded indication for the poly(adenosine diphosphate–ribose) polymerase ...
OCTOBER 28, 2019
FDA Approves Niraparib for Recurrent Ovarian Cancer
Unlike other PARP inhibitors, niraparib is active in both patients with and without BRCA mutations.
MARCH 29, 2017
Load more